MINAKEM SAS
Minakem SAS is a France-based pharmaceutical CDMO manufacturing Active Pharmaceutical Ingredients (APIs), including highly potent compounds, steroids, and controlled substances, for global pharmaceutical and generic drug companies across four cGMP sites in France, Belgium, and Canada.
- Company typePrivate
- Founded1964
- HeadquartersBeuvry, France
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What MINAKEM SAS does
Minakem SAS is a France-based Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs), including Highly Potent APIs (HPAPIs), controlled substances, steroids, and complex small molecules. The company operates four cGMP-compliant production sites — two in France (Beuvry-la-Forêt and Dunkerque), one in Belgium (Louvain-la-Neuve), and one in Canada (Montreal) — representing over 500 m³ of total reaction capacity, with exports to 35 countries and a portfolio of more than 100 Drug Master Files across the US, EU, Japan, China, Korea, and Canada. Minakem's core technical capabilities include HPAPI manufacturing at OEB5 containment levels (OEL down to 0.1 µg/m³), industrial preparative HPLC purification, cryogenic reactions to -80°C, advanced chiral and organometallic synthesis, solid-state chemistry, and corticosteroid manufacturing, with a 2024 fully automated facility at Beuvry-la-Forêt representing the latest capital investment.
The company generates revenue through a hybrid CDMO/generic API model: project-based custom development and manufacturing fees from pharmaceutical clients, complemented by recurring commercial supply of a generic API portfolio spanning oncology (vinca alkaloids), cardiovascular, CNS, gastrointestinal, and veterinary therapeutic areas. Long-term supply agreements, DMF-backed qualifications, and the addition of GMP excipients and building blocks as adjacent product lines reinforce an integrated go-to-market approach. Distribution is exclusively direct B2B, with sales driven by industry trade shows (BePharma, DCAT Week, CPhI), regulatory qualification, and technical engagement rather than intermediaries.
Minakem is a wholly-owned subsidiary of Minafin Group, a diversified chemical group, and has grown primarily through acquisition — the Beuvry-la-Forêt site (2005), the former AstraZeneca Dunkirk plant (2009), the Ajinomoto Omnichem Louvain-la-Neuve site (2015), and the Delmar Chemicals Montreal facility (2023). The company holds 501-1,000 employees and is led by Olivier Ubrich, appointed CEO of the Health Chemistry Division of Minafin Group in September 2024. Certifications across cGMP, USFDA, EDQM, Health Canada, AFMPS, ISO 27001, and multiple quality/religious certifications (Halal, Kosher, non-GMO) support multinational pharmaceutical client requirements.
MINAKEM SAS firmographics
Firmographics- Name
- MINAKEM SAS
- Legal name
- Minakem SAS
- Website
- https://minakem.com
- Company type
- Private
- Founded year
- 1964
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Minakem SAS is a France-based pharmaceutical CDMO manufacturing Active Pharmaceutical Ingredients (APIs), including highly potent compounds, steroids, and controlled substances, for global pharmaceutical and generic drug companies across four cGMP sites in France, Belgium, and Canada.
- Ownership category
- akta.pro rank
MINAKEM SAS industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- High-Potency API (HPAPI) Development & Manufacturing (HLAGAHAC), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where MINAKEM SAS is headquartered
LocationHeadquarters
- HQ city
- Beuvry
- HQ country
- France
- HQ region
- Europe
Offices4 records
Markets served
MINAKEM SAS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- API Manufacturing Services: Minakem generates revenue through custom development and manufacturing of Active Pharmaceutical Ingredients (APIs) for pharmaceutical companies. Revenue is earned through project-based development fees, technology transfer services, and long-term commercial supply agreements. The company operates on a CDMO model where clients pay for process development, scale-up, and manufacturing services, typically under multi-year supply contracts with recurring revenue from approved API sources.
- Generic API Supply: Revenue from the commercial supply of generic APIs from the company's portfolio, including steroids, controlled substances, Vinca alkaloids, and other small molecule APIs. Supply agreements typically involve recurring orders as pharmaceutical formulations receive regulatory approval.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom API Development and Manufacturing - Quote-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
MINAKEM SAS product offering
Product offeringCore offering
Minakem is a B2B Contract Development and Manufacturing Organization (CDMO) that develops and manufactures Active Pharmaceutical Ingredients (APIs), including highly potent APIs (HPAPIs), controlled substances, and steroids, for pharmaceutical companies worldwide. It provides custom process development, analytical method development, scale-up, technology transfer, and commercial supply from four cGMP-compliant production facilities in France, Belgium, and Canada. Its portfolio also includes more than 30 generic APIs, GMP excipients, and chemical building blocks for organic synthesis.
Product overview
MINAKEM SAS is a Contract Development and Manufacturing Organization (CDMO) providing comprehensive pharmaceutical manufacturing services. The company operates as a single unified offering combining API Manufacturing Services, API Development Services, Analytical Sciences, and Specialized Technologies including Highly Potent APIs (HPAPIs) and Solid State Chemistry. Their portfolio includes over 30 generic Active Pharmaceutical Ingredients across therapeutic areas including oncology (Vinblastine, Vincristine, Vindesine, Vinorelbine), cardiovascular, gastrointestinal, and veterinary applications, complemented by Building Blocks for organic synthesis and GMP Excipients. The company operates four manufacturing facilities across France (Beuvry-la-Forêt and Dunkerque), Belgium (Louvain-la-Neuve), and Canada (Montreal), serving customers in 35 countries with cGMP-compliant production from gram to multi-ton scale.
Differentiator
Problem solved
Functional benefit
Products and services
- API Manufacturing Services Contract development and manufacturing services for Active Pharmaceutical Ingredients (APIs) including small molecule APIs, HPAPIs, controlled substances, and steroids, spanning from clinical to commercial scale at four cGMP-compliant production sites in France, Belgium, and Canada. Targeted at pharmaceutical companies needing reliable, long-term API supply.
- API Development Services Comprehensive API development including process design, scale-up, and analytical development for custom small molecule and HPAPI projects from discovery through commercialization, intended for pharmaceutical companies outsourcing route scouting, process optimization, and technology transfer.
- Analytical Sciences Analytical method development, validation, and testing services that support API manufacturing and regulatory submissions, available to pharmaceutical customers across all four Minakem production sites.
- Highly Potent APIs (HPAPIs) Development and manufacturing of highly potent active pharmaceutical ingredients with OEL limits down to 0.1 µg/m³, including cytotoxic and cytostatic compounds, produced under strict OEB5 containment conditions for oncology and other high-potency pharmaceutical applications.
- Solid State Chemistry Services Solid state characterization, polymorph screening, crystallization process development, particle size optimization, and intellectual property support for API development customers.
- Specialized Chemical Reactions Advanced chemical synthesis services including cryogenic reactions (down to -80°C), cyanation, halogenation, hydrogenation, carbonylation, fractional distillation, and preparative chromatography for complex API manufacturing projects.
- Building Blocks Catalog product of chemical intermediates and building blocks for organic synthesis, including cyclobutane derivatives, cyclopropyl compounds, tetrahydropyran derivatives, and other specialized reagents for pharmaceutical synthesis customers.
- GMP Excipients Pharmaceutical-grade excipients product line including Sodium Stearyl Fumarate GMP and Propyl gallate GMP, meeting USP and EP standards for pharmaceutical formulation customers.
- Generic APIs Portfolio Portfolio of more than 30 generic active pharmaceutical ingredients supplied under cGMP, including APIs for oncology (vinca alkaloids: Vinblastine, Vincristine, Vindesine, Vinorelbine), cardiovascular, central nervous system, gastrointestinal, and veterinary applications, sold directly to generic drug manufacturers.
Quantifiable outcome
- Successful FDA inspection completed at Montreal facility (November 2025)
- +2 more outcomes
Companies that use MINAKEM SAS
Customer profileSegments2 records
Ideal customer profiles2 records
MINAKEM SAS technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
MINAKEM SAS partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Delmar Chemicals Inc. (Acquisition by Minafin Group)coreMinafin Group acquired Delmar Chemicals Inc. in Montreal, Canada in July 2023 to expand its Healthcare Chemicals division and establish presence in North America. The acquisition includes a portfolio of generic active pharmaceutical ingredients and enhances R&D and manufacturing capacities, especially in organic synthesis and corticosteroids. This enables Minakem to serve the North American market directly.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
MINAKEM SAS competitors and assessment
Company assessmentDirect peers
- Hovione: Hovione is a privately held, Portugal-based CDMO specializing in small-molecule APIs and HPAPIs with manufacturing in Europe and the U.S. It is the closest functional comparable to Minakem in terms of HPAPI containment levels, complex chemistry (cryogenic, particle engineering) and CDMO-plus-generics mix.
- Siegfried Holding: Siegfried is a Swiss-listed CDMO offering API manufacturing plus finished dosage forms with sites in Switzerland, the U.S., Germany, Spain and Malta. Comparable to Minakem in small-molecule API CDMO model and global multi-site footprint, though larger and more integrated into drug product.
- EuroAPI: EuroAPI is a French API manufacturer spun out of Sanofi, focused on small-molecule APIs and intermediates across steroids, hormones and complex chemistry. It mirrors Minakem's European footprint, steroid franchise and CDMO activity, and is a directly comparable European API specialist competitor.
- Seqens (PCAS): Seqens is a France-based specialty chemicals and pharmaceutical CDMO producing APIs, intermediates and complex molecules across multiple sites. It is comparable to Minakem as a French-headquartered, multi-site API CDMO serving global pharma with similar chemistry capabilities.
- Cambrex: Cambrex is a U.S.-headquartered CDMO focused exclusively on small-molecule APIs and intermediates with HPAPI capabilities across North America and Europe. Acquired by Permira/Novo Holdings, it competes head-on with Minakem in custom API development, scale-up and commercial supply.
- Veranova (formerly Johnson Matthey Health): Veranova is a CDMO spun out of Johnson Matthey in 2023 specializing in HPAPIs, complex APIs and antibody-drug conjugate payloads. It is highly comparable to Minakem given shared HPAPI focus, containment capabilities and oncology customer base.
- CARBOGEN AMCIS (Dishman): CARBOGEN AMCIS is a Switzerland/India-headquartered CDMO with strong HPAPI capabilities, complex chemistry and a global API manufacturing network. Comparable to Minakem in HPAPI containment, complex synthesis and integrated development-to-commercial services.
Broad incumbents
- Lonza Small Molecules: Lonza operates the world's largest CDMO franchise spanning small-molecule APIs, biologics and cell & gene therapies. Its small-molecules division competes directly with Minakem in API development and HPAPI manufacturing but offers a far broader integrated services portfolio.
- Catalent: Catalent (now under Novo Holdings) is a global CDMO offering drug substance (including HPAPI) and drug product services across biologics, softgel and inhalation. It overlaps with Minakem in HPAPI and small-molecule API CDMO but is much larger and more diversified.
Emerging players
- Aurobindo / Apitoria Pharma: Aurobindo and its CDMO arm Apitoria operate large-scale generic API manufacturing globally, including corticosteroids and complex small molecules. Comparable to Minakem's generic API supply business, though with a much larger commercial-scale footprint and broader finished-dose integration.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MINAKEM SAS social profiles
Digital presenceMINAKEM SAS compliance and trust
Trust signalCompliance12 records
MINAKEM SAS financial estimates
Financial estimateRevenue estimate
Valuation estimate
MINAKEM SAS leadership team
Management profileNumber of profiles
Profiles5 records
MINAKEM SAS subsidiaries and ownership
Company hierarchySubsidiaries1 record
MINAKEM SAS funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MINAKEM SAS M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MINAKEM SAS
What does MINAKEM SAS do?
Minakem is a B2B Contract Development and Manufacturing Organization (CDMO) that develops and manufactures Active Pharmaceutical Ingredients (APIs), including highly potent APIs (HPAPIs), controlled substances, and steroids, for pharmaceutical companies worldwide. It provides custom process development, analytical method development, scale-up, technology transfer, and commercial supply from four cGMP-compliant production facilities in France, Belgium, and Canada. Its portfolio also includes more than 30 generic APIs, GMP excipients, and chemical building blocks for organic synthesis.
Is MINAKEM SAS a public or private company?
MINAKEM SAS is a private company. It is classified as corporate owned and is currently operating.
When was MINAKEM SAS founded?
MINAKEM SAS was founded in 1964. It employs 501 to 1,000 people.
Where is MINAKEM SAS based?
MINAKEM SAS is headquartered in Beuvry, France, in the Europe region.
How does MINAKEM SAS make money?
Two revenue lines are on record. API Manufacturing Services are the primary driver. The others are generic API Supply.
Who are MINAKEM SAS's main competitors?
Direct peers on record are Hovione, Siegfried Holding, EuroAPI, Seqens (PCAS), Cambrex, Veranova (formerly Johnson Matthey Health) and CARBOGEN AMCIS (Dishman). Broad incumbents are Lonza Small Molecules and Catalent. Aurobindo / Apitoria Pharma is listed as an emerging player.
Does MINAKEM SAS have an API?
No public API is recorded for MINAKEM SAS.
What industry is MINAKEM SAS in?
MINAKEM SAS's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAC, High-Potency API (HPAPI) Development & Manufacturing. Its NAICS code is 32541 and its SIC code is 2833.